A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients
Therapeutic management of solid organ transplant (SOT) recipients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), may challenge healthcare providers given a paucity of clinical data specific to this cohort. Herein, we summ...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/9/1706 |
| _version_ | 1797517026254651392 |
|---|---|
| author | Deanna J. Buehrle Robert R. Sutton Erin L. McCann Aaron E. Lucas |
| author_facet | Deanna J. Buehrle Robert R. Sutton Erin L. McCann Aaron E. Lucas |
| author_sort | Deanna J. Buehrle |
| collection | DOAJ |
| description | Therapeutic management of solid organ transplant (SOT) recipients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), may challenge healthcare providers given a paucity of clinical data specific to this cohort. Herein, we summarize and review the studies that have formed the framework for current COVID-19 consensus management guidelines. Our review focuses on COVID-19 treatment options including monoclonal antibody products, antiviral agents such as remdesivir, and immunomodulatory agents such as corticosteroids, interleukin inhibitors, and kinase inhibitors. We highlight the presence or absence of clinical data of these therapeutics related to the SOT recipient with COVID-19. We also describe data surrounding COVID-19 vaccination of the SOT recipient. Understanding the extent and limitations of observational and clinical trial data for the prevention and treatment of COVID-19 specific to the SOT population is crucial for optimal management. Although minimal data exist on clinical outcomes among SOT recipients treated with varying COVID-19 therapeutics, reviewing these agents and the studies that have led to their inclusion or exclusion in clinical management of COVID-19 highlights the need for further studies of these therapeutics in SOT patients with COVID-19. |
| first_indexed | 2024-03-10T07:09:12Z |
| format | Article |
| id | doaj.art-fccb3d573c2249e7b3d57c878a46cd57 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T07:09:12Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-fccb3d573c2249e7b3d57c878a46cd572023-11-22T15:36:46ZengMDPI AGViruses1999-49152021-08-01139170610.3390/v13091706A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant RecipientsDeanna J. Buehrle0Robert R. Sutton1Erin L. McCann2Aaron E. Lucas3Department of Medicine, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15240, USADepartment of Pharmacy, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15240, USADepartment of Pharmacy, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15240, USADepartment of Medicine, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15240, USATherapeutic management of solid organ transplant (SOT) recipients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), may challenge healthcare providers given a paucity of clinical data specific to this cohort. Herein, we summarize and review the studies that have formed the framework for current COVID-19 consensus management guidelines. Our review focuses on COVID-19 treatment options including monoclonal antibody products, antiviral agents such as remdesivir, and immunomodulatory agents such as corticosteroids, interleukin inhibitors, and kinase inhibitors. We highlight the presence or absence of clinical data of these therapeutics related to the SOT recipient with COVID-19. We also describe data surrounding COVID-19 vaccination of the SOT recipient. Understanding the extent and limitations of observational and clinical trial data for the prevention and treatment of COVID-19 specific to the SOT population is crucial for optimal management. Although minimal data exist on clinical outcomes among SOT recipients treated with varying COVID-19 therapeutics, reviewing these agents and the studies that have led to their inclusion or exclusion in clinical management of COVID-19 highlights the need for further studies of these therapeutics in SOT patients with COVID-19.https://www.mdpi.com/1999-4915/13/9/1706solid organ transplantCOVID-19vaccineSARS-CoV-2immunosuppressed |
| spellingShingle | Deanna J. Buehrle Robert R. Sutton Erin L. McCann Aaron E. Lucas A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients Viruses solid organ transplant COVID-19 vaccine SARS-CoV-2 immunosuppressed |
| title | A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients |
| title_full | A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients |
| title_fullStr | A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients |
| title_full_unstemmed | A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients |
| title_short | A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients |
| title_sort | review of treatment and prevention of coronavirus disease 2019 among solid organ transplant recipients |
| topic | solid organ transplant COVID-19 vaccine SARS-CoV-2 immunosuppressed |
| url | https://www.mdpi.com/1999-4915/13/9/1706 |
| work_keys_str_mv | AT deannajbuehrle areviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients AT robertrsutton areviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients AT erinlmccann areviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients AT aaronelucas areviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients AT deannajbuehrle reviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients AT robertrsutton reviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients AT erinlmccann reviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients AT aaronelucas reviewoftreatmentandpreventionofcoronavirusdisease2019amongsolidorgantransplantrecipients |